Cargando…
Epitopes Predominantly Retained on the Carcinoembryonic Antigen Molecules in Plasma of Patients with Malignant Tumors but Not on Those in Plasma of Normal Individuals
We have previously reported that a group of monoclonal antibodies (MAbs) to carcinoembryonic antigen (CEA), designated Group F MAbs, are able to discriminate CEA in tumor tissues from normal fecal antigen(2), a soluble form CEA‐counterpart in normal adult feces, and that the protein epitopes recogni...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918852/ https://www.ncbi.nlm.nih.gov/pubmed/1377668 http://dx.doi.org/10.1111/j.1349-7006.1992.tb01957.x |
Sumario: | We have previously reported that a group of monoclonal antibodies (MAbs) to carcinoembryonic antigen (CEA), designated Group F MAbs, are able to discriminate CEA in tumor tissues from normal fecal antigen(2), a soluble form CEA‐counterpart in normal adult feces, and that the protein epitopes recognized by them are present on the domain A3‐B3 of the CEA molecule. In this study, we further investigated the molecular localization of the epitopes recognized by the Group F MAbs using three new recombinant CEA proteins with restricted domain structures expressed in Chinese hamster ovary cells, and found that the epitopes for the Group F MAbs are present on domain B3 close to the anchoring device of the CEA molecule. The epitopes for the Group F MAbs were retained on the CEA molecules in the plasma of patients with malignant tumors and on the CEA molecules spontaneously released into the culture media from established tumor cell lines. However, a large part of the CEA molecules in the plasma of normal individuals were found to lack the epitopes for the Group F MAbs. These results provide a basis for the improved cancer diagnosis by using our CEA assay system utilizing a Group F MAb, and indicate the potential clinical utility of the Group F MAbs. |
---|